The role of epigenetics in the biology of multiple myeloma

por Dimopoulos, K, Gimsing, P, Grønbæk, K
Publicado 2014

P1723: A FEASIBILITY STUDY OF PEER SUPPORT IN FAMILY CAREGIVERS OF PATIENTS NEWLY DIAGNOSED WITH HEMATOLOGIC MALIGNANCY

por Nielsen, I. H., Piil, K., Kjeldsen, L., Grønbæk, K., Jarden, M.
Publicado 2022

P1246: DIFFERENTIAL ROLE OF MICROENVIRONMENT AND STROMAL-CELL INDUCED VENETOCLAX RESISTANCE IN MANTLE CELL LYMPHOMA

por Andersen, P., Granau, A., Jakobsen, T., Sommer Kristensen, L., Bay Mogensen, J., Dimopoulos, K., Grønbæk, K.
Publicado 2022

P1259: CHARACTERIZATION OF VENETOCLAX RESISTANCE IN CELL MODELS OF MANTLE CELL LYMPHOMA

por Granau, A., Andersen, P., Jakobsen, T., Sommer Kristensen, L., Bay Mogensen, J., Dias Correa Guldbergsen, G., Dimopoulos, K., Grønbæk, K.
Publicado 2022

5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies

por Gang, A O, Frøsig, T M, Brimnes, M K, Lyngaa, R, Treppendahl, M B, Grønbæk, K, Dufva, I H, Straten, P thor, Hadrup, S R
Publicado 2014

P1264: HEMATOPOIETIC CLONES WITH TP53 MUTATIONS EXPAND IN PATIENTS WITH MCL DURING LENALIDOMIDE-BASED THERAPY

por Husby, S., Bæch-Laursen, C., Favero, F., Jespersen, J. S., Eskelund, C. W., Hutchings, M., Pedersen, L. B., Niemann, C. U., Weischenfeldt, J., Geisler, C., Räty, R., Larsen, T. S., Kolstad, A., Jerkeman, M., Grønbæk, K.
Publicado 2022

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial

por Tobiasson, M, Dybedahl, I, Holm, M S, Karimi, M, Brandefors, L, Garelius, H, Grövdal, M, Högh-Dufva, I, Grønbæk, K, Jansson, M, Marcher, C, Nilsson, L, Kittang, A O, Porwit, A, Saft, L, Möllgård, L, Hellström-Lindberg, E
Publicado 2014